Objective: The MINERVA trial showed that in pacemaker patients with atrial fibrillation (AF) history, DDDRP pacing combining three algorithms – (a) atrial antitachycardia pacing with Reactive ATP enabled, (b) atrial preventive pacing and (c) managed ventricular pacing (MVP)—may effectively delay progression to persistent/permanent AF compared with standard DDDR pacing. We performed a comparative non-randomised evaluation to evaluate if Reactive ATP can be the main driver of persistent/permanent AF reduction independently on preventive pacing. Methods: Thirty-one centres included consecutive dual-chamber pacemaker patients with AF history. Reactive ATP was programmed in all patients while preventive atrial pacing was not enabled. These patients were compared with the three groups of MINERVA randomised trial (Control DDDR, MVP, and DDDRP). The main endpoint was the incidence of AF longer than 7 consecutive days. Results: A total of 146 patients (73 years old, 54% male) were included and followed for a median observation period of 31 months. The 2-year incidence of AF > 7 days was 12% in the Reactive ATP group, very similar to that found in the DDDRP arm of the MINERVA trial (13.8%, P =.732) and significantly lower than AF incidence found in the MINERVA Control DDDR arm (25.8%, P =.012) and in the MINERVA MVP arm (25.9%, P =.025). Conclusions: In a real-world population of dual-chamber pacemaker patients with AF history, the use of Reactive ATP is associated with a low incidence of persistent AF, highlighting that the positive results of the MINERVA trial were related to the effectiveness of Reactive ATP rather than to preventive pacing.

Prevention of long-lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers / Boriani, G.; Sakamoto, Y.; Botto, G.; Komura, S.; Pieragnoli, P.; Minamiguchi, H.; Iacopino, S.; Noma, T.; Infusino, T.; Takahashi, Y.; Facchin, D.; De Rosa, F.; Pisano, E.; Meloni, S.; Biffi, M.. - In: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. - ISSN 1368-5031. - 75:3(2021), pp. 1-9. [10.1111/ijcp.13820]

Prevention of long-lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers

Boriani G.;Botto G.;De Rosa F.;Meloni S.;
2021

Abstract

Objective: The MINERVA trial showed that in pacemaker patients with atrial fibrillation (AF) history, DDDRP pacing combining three algorithms – (a) atrial antitachycardia pacing with Reactive ATP enabled, (b) atrial preventive pacing and (c) managed ventricular pacing (MVP)—may effectively delay progression to persistent/permanent AF compared with standard DDDR pacing. We performed a comparative non-randomised evaluation to evaluate if Reactive ATP can be the main driver of persistent/permanent AF reduction independently on preventive pacing. Methods: Thirty-one centres included consecutive dual-chamber pacemaker patients with AF history. Reactive ATP was programmed in all patients while preventive atrial pacing was not enabled. These patients were compared with the three groups of MINERVA randomised trial (Control DDDR, MVP, and DDDRP). The main endpoint was the incidence of AF longer than 7 consecutive days. Results: A total of 146 patients (73 years old, 54% male) were included and followed for a median observation period of 31 months. The 2-year incidence of AF > 7 days was 12% in the Reactive ATP group, very similar to that found in the DDDRP arm of the MINERVA trial (13.8%, P =.732) and significantly lower than AF incidence found in the MINERVA Control DDDR arm (25.8%, P =.012) and in the MINERVA MVP arm (25.9%, P =.025). Conclusions: In a real-world population of dual-chamber pacemaker patients with AF history, the use of Reactive ATP is associated with a low incidence of persistent AF, highlighting that the positive results of the MINERVA trial were related to the effectiveness of Reactive ATP rather than to preventive pacing.
2021
9-nov-2020
75
3
1
9
Prevention of long-lasting atrial fibrillation through antitachycardia pacing in DDDR pacemakers / Boriani, G.; Sakamoto, Y.; Botto, G.; Komura, S.; Pieragnoli, P.; Minamiguchi, H.; Iacopino, S.; Noma, T.; Infusino, T.; Takahashi, Y.; Facchin, D.; De Rosa, F.; Pisano, E.; Meloni, S.; Biffi, M.. - In: INTERNATIONAL JOURNAL OF CLINICAL PRACTICE. - ISSN 1368-5031. - 75:3(2021), pp. 1-9. [10.1111/ijcp.13820]
Boriani, G.; Sakamoto, Y.; Botto, G.; Komura, S.; Pieragnoli, P.; Minamiguchi, H.; Iacopino, S.; Noma, T.; Infusino, T.; Takahashi, Y.; Facchin, D.; De Rosa, F.; Pisano, E.; Meloni, S.; Biffi, M.
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

Licenza Creative Commons
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/11380/1227039
Citazioni
  • ???jsp.display-item.citation.pmc??? 0
  • Scopus 2
  • ???jsp.display-item.citation.isi??? 2
social impact